For all inquiries regarding Tissue Microarrays with survival data, please contact us at support@taibsbio.cn
RLN2502
询问
显微镜观察:

/

一般观察:

1.Exploration revealed no pleural effusion or adhesions. The lung fissures were well developed. A lesion was located in the apicoposterior segment of the left upper lobe, with pleural retraction at the site of the lesion. 2.The tumor measured approximat

病理学诊断:

Left Upper Lobe Resection Specimen: 1.(Left) Lung (upper lobe): Peripheral malignant tumor. The histological and immunophenotypic features are consistent with adenosquamous carcinoma. The tumor invades the pleura. 2.Bronchial stump: No carcinoma identif

总体检查结果:

1.Left upper lobe resection specimen measuring 20 × 11 × 2.5 cm. 2.A peripheral tumor was identified 1.5 cm from the bronchial stump, which had been previously sectioned intraoperatively, measuring 3.0 × 3.0 × 2.5 cm. 3.The cut surface appeared gray-whi

年龄:67

性别:

手术日期:2021.07.19

个人历史:Diagnosed with tuberculosis 6 months ago; currently on regular anti-tuberculosis therapy. History of lacunar cerebral infarction for 10 years. No history of exposure to dust, toxins, or radioactive substances.

家族史:Father deceased (cause unknown); mother and children are healthy.

吸烟和饮酒史:

肿瘤大小:3.0cmx3.0cmx2.5cm

组织学诊断:Mediastinoscopy was not performed. On July 9, 2021, a bronchoscopy was conducted, and pathology from the left upper lobe biopsy revealed non–small cell lung carcinoma (NSCLC), favoring poorly differentiated squamous cell carcinoma.

免疫组织化学:CK5/6 (+), p40 (+), CK7 (+), CK18 (+), Ki-67 (+, focal ~60%), MLH1 (+), PMS2 (+), MSH6 (+), MSH2 (+), EMA (+), SP-B (+, few cells), TTF-1 (+, partial cells), Vimentin (−), Syn (−), CD34 (−), D2-40 (−).

等级:II

分期:T2aN0M0

阶段:IB

格里森评分:/

格里森等级:/

肿瘤含量 (%):0.7

坏死内容物 (%):0

治疗方案:Systemic chemotherapy

疾病进展:Chemotherapy Regimen: Paclitaxel (albumin-bound): 300 mg IV on Day 1 Cisplatin: 100 mg IV on Day 1 First cycle: October 7, 2021 Planned total: 6 cycles

跟进:Alive

0.045903s